A phase I dose-ranging study of the safety, tolerability, and immunogenicity of the Merck trivalent adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in a prime-boost regimen in healthy adults
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2006
At a glance
- Drugs V 520 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 08 Feb 2006 New trial record.